UK Markets open in 3 hrs 40 mins
NIKKEI 225
27,342.48 +15.37 (+0.06%) HANG SENG
21,902.35 +60.02 (+0.27%) CRUDE OIL
79.30 +0.43 (+0.55%) GOLD FUTURES
1,943.20 -2.10 (-0.11%) DOW
34,086.04 +368.95 (+1.09%) BTC-GBP
18,777.19 +157.04 (+0.84%)
Alzamend Neuro, Inc. (ALZN)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
At close: 03:59PM EST
After hours:
| Previous close | 0.6611 |
| Open | 0.6611 |
| Bid | 0.6700 x 1000 |
| Ask | 0.7069 x 800 |
| Day's range | 0.6525 - 0.7003 |
| 52-week range | 0.4900 - 1.5800 |
| Volume | |
| Avg. volume | 374,200 |
| Market cap | 58.97M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1030 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 11.13 |
- Business Wire
Alzamend Neuro to Present at Sequire Biotechnology Conference
ATLANTA, January 26, 2023--Alzamend Neuro to Present at Sequire Biotechnology Conference on Thursday, February 2, 2023; Highlighting Alzamend’s Achievements This Past Year
- Business Wire
Alzamend Neuro Partners With Biorasi to Conduct a First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase I/IIA Clinical Trial
ATLANTA, January 04, 2023--Alzamend Neuro Partners With Biorasi to Conduct First-in-Human, Randomized, Double-Blind Placebo-Controlled Parallel Group Phase I/IIA Clinical Trial
- Business Wire
Alzamend Neuro Partners With the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for ALZN002 Phase I/IIA Immunotherapy Vaccine Clinical Trial to Treat Mild to Moderate Dementia of the Alzheimer’s Type
ATLANTA, December 28, 2022--Alzamend Neuro Partners with Miller School of Medicine at the University of Miami for ALZN002 Phase I/IIA Immunotherapy Vaccine Clinical Trial for AD
© 2023 Yahoo. All rights reserved.
